We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -10.00% | 9.00 | 8.00 | 10.00 | 9.00 | 9.00 | 9.00 | 670,146 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -1.06 | 35.01M |
TIDMREDX
Redx Pharma plc
03 January 2019
REDX PHARMA PLC
("Redx" or "the Company")
Redx to present at 2019 Biotech Showcase event in San Francisco
Alderley Park, 3 January 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that Lisa Anson, Chief Executive Officer and Dr Andrew Saunders, Chief Medical Officer will be presenting at Biotech Showcase in San Francisco, which runs from 7 - 9 January 2019. Lisa Anson joined Redx from a senior role at AstraZeneca in mid-2018 with a remit to relaunch the Company. This will be the first time that she will present the Company in the US as Redx's CEO. Andrew Saunders will provide an update on the Company's clinical Oncology programme. The team will also be joined by Dr. Peter Bunyard, Head of Fibrosis, following the announcement of the Company's first fibrosis development candidate, RXC006, in November 2018.
Redx's presentation will take place at 3pm PST on Tuesday 8 January 2019 at the Hilton, Union Square in San Francisco, California, Track: Yosemite A (Ballroom Level).
Lisa Anson, Chief Executive Officer, Redx Pharma plc commented: "I am delighted that Redx has been asked to present at the Biotech Showcase event in January. The event is a great opportunity to share with potential US investors and partners how far we have progressed in 2018 and our forthcoming milestones and plans for 2019."
For further information, please contact:
Hot Features
Premium
Redx Pharma Plc T: +44 1625 469
920
Lisa Anson, Chief Executive Officer
Andrew Saunders, Chief Medical Officer
Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894
Joint Broker) 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRAUAVRRWKAUUAA
(END) Dow Jones Newswires
January 03, 2019 02:00 ET (07:00 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
